Relationship of Depression, Anxiety and Quality of Life with Disease Activity in Ankylosing Spondylitis Patients Receiving Biological Therapy Biyolojik Tedavi Alan Ankilozan Spondilit Hastalarında Depresyon, Anksiyete ve Yaşam Kalitesinin Hastalık Aktivitesiyle İlişkisi
Journal of Uludag University Medical Faculty, cilt.50, sa.3, ss.411-418, 2024 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 50 Sayı: 3
- Basım Tarihi: 2024
- Doi Numarası: 10.32708/uutfd.1566198
- Dergi Adı: Journal of Uludag University Medical Faculty
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.411-418
- Anahtar Kelimeler: Activity, Ankylosing spondylitis, Anxiety, BASDAI, BASFI, Depression
- Bursa Uludağ Üniversitesi Adresli: Evet
Özet
Ankylosing spondylitis (AS) is a chronic inflammatory disease that leads to structural damage and functional limitations in the axial skeleton. The progressive nature of the disease often results in a clinical picture where psychiatric symptoms, such as depression and anxiety, frequently co-occur. The aim of this study is to investigate the relationship between disease activity, depression, anxiety, and quality of life in patients with AS. A cross-sectional analysis was conducted on 153 patients diagnosed with AS according to the Modified New York criteria. Disease activity was assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), and functional status was evaluated with the Bath Ankylosing Spondylitis Functional Index (BASFI). Depression and anxiety levels were measured using the Beck Depression Inventory (BDI) and the Hospital Anxiety and Depression Scale (HADS). Quality of life was assessed using the SF-36 questionnaire. In patients with BASDAI≥4, significant decreases were observed in several SF-36 domains, including physical function (p = 0.006), social function (p=0.001), physical role limitation (p=0.013), emotional role limitation (p=0.024), and pain (p=0.001). However, no significant difference was found between disease activity and depression or anxiety scores. Additionally, no correlation was observed between BASDAI or BASFI and psychological symptoms. It was noted that higher disease activity has a markedly negative impact on the quality of life in AS patients. However, the absence of an increase in depression and anxiety levels in patients under biological treatment suggests that these therapies may help control psychiatric symptoms. The detrimental effect of disease activity on quality of life in AS patients is evident. Biological treatments, by controlling depression and anxiety, appear to support better quality of life. A holistic approach is essential in the management of AS.